effective
vaccine.
One
candidate
known as
DS-Cavl
developed
by Dr.
Barney
Graham’s
team at
NIAID’s
Vaccine
Research
Center
has shown
early
promise
ina
Phase l
clinical
trial.

I’m CCing my
public affairs
colleagues who
liaise with
these topics
in case there
is follow up.
Looking
forward to
hopefully
meeting you
when you
visit.

Thanks,

Anne

From: Jason
Gale
(BLOOMBERG /
NEWSROOM: )

<j .gale@bloomb

erg.net>

NIH-001410
